AstraZeneca (AZN) Revenue & Revenue Breakdown

AstraZeneca's yearly revenue for 2023 was $45.81B, representing an increase of 3.29% compared to 2022. The company's yearly revenue for 2022 was $44.35B, representing an increase of 18.53% compared to 2021. AZN's yearly revenue for 2021 was $37.42B, representing an increase of 40.58% compared to 2020.

AstraZeneca's quarterly revenue for Q1 2024 was $12.68B, a 5.45% increase from the previous quarter (Q4 2023), and a 16.55% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $12.02B, a 4.63% increase from the previous quarter (Q3 2023), and a 7.29% increase year-over-year (Q4 2022). AZN's quarterly revenue for Q3 2023 was $11.49B, a 0.67% increase from the previous quarter (Q2 2023), and a 4.64% increase year-over-year (Q3 2022).

AstraZeneca's revenue growth rate for the last 3 years (2021-2023) was 22.43%, and for the last 5 years (2019-2023) was 87.87%.

AstraZeneca's revenue streams in c 23 are Pulmicort, Roxadustat, Saphnelo, Seloken/Toprol-XL, Soliris, Strensiq, Andexxa, Zoladex, Vaxzevria, Ultomiris., Total Other medicines, Total Oncology, Tagrisso, Synagis, Symbicort, Enhertu, Bevespi, Breztri, Brilinta, Bydureon, CVRM, Calquence, Crestor, Daliresp/Daxas, Farxiga, Fasenra, Faslodex, FluMist, Imfinzi, Kanuma, Koselugo, Lokelma, Lynparza, Nexium, Oncology, Others, Onglyza, Other, Others, and Rare Disease. Pulmicort generated $713M in revenue, accounting 0.89% of the company's total revenue, up 10.54% year-over-year. Roxadustat generated $271M in revenue, accounting 0.34% of the company's total revenue, up 37.56% year-over-year. Saphnelo generated $280M in revenue, accounting 0.35% of the company's total revenue, up 141.38% year-over-year. Seloken/Toprol-XL generated $640M in revenue, accounting 0.80% of the company's total revenue, down -25.75% year-over-year. Soliris generated $3.14B in revenue, accounting 3.92% of the company's total revenue, down -16.40% year-over-year. Strensiq generated $1.15B in revenue, accounting 1.44% of the company's total revenue, up 20.25% year-over-year. Andexxa generated $182M in revenue, accounting 0.23% of the company's total revenue, up 21.33% year-over-year. Zoladex generated $952M in revenue, accounting 1.19% of the company's total revenue, up 2.70% year-over-year. Vaxzevria generated $12M in revenue, accounting 0.01% of the company's total revenue, down -99.33% year-over-year. Ultomiris. generated $2.96B in revenue, accounting 3.70% of the company's total revenue, up 50.89% year-over-year. Total Other medicines generated $1.18B in revenue, accounting 1.47% of the company's total revenue, down -27.63% year-over-year. Total Oncology generated $17.14B in revenue, accounting 21.37% of the company's total revenue, up 17.18% year-over-year. Tagrisso generated $5.8B in revenue, accounting 7.23% of the company's total revenue, up 6.52% year-over-year. Synagis generated $546M in revenue, accounting 0.68% of the company's total revenue, down -5.54% year-over-year. Symbicort generated $2.36B in revenue, accounting 2.94% of the company's total revenue, down -6.93% year-over-year. Enhertu generated $1.02B in revenue, accounting 1.27% of the company's total revenue, up 1193.67% year-over-year. Bevespi generated $58M in revenue, accounting 0.07% of the company's total revenue Breztri generated $677M in revenue, accounting 0.84% of the company's total revenue, up 70.10% year-over-year. Brilinta generated $1.32B in revenue, accounting 1.65% of the company's total revenue, down -2.50% year-over-year. Bydureon generated $163M in revenue, accounting 0.20% of the company's total revenue, down -41.79% year-over-year. CVRM generated $10.58B in revenue, accounting 13.19% of the company's total revenue, up 15.20% year-over-year. Calquence generated $2.51B in revenue, accounting 3.13% of the company's total revenue, up 22.22% year-over-year. Crestor generated $1.11B in revenue, accounting 1.38% of the company's total revenue, up 5.63% year-over-year. Daliresp/Daxas generated $54M in revenue, accounting 0.07% of the company's total revenue, down -71.43% year-over-year. Farxiga generated $5.96B in revenue, accounting 7.43% of the company's total revenue, up 36.11% year-over-year. Fasenra generated $1.55B in revenue, accounting 1.94% of the company's total revenue, up 11.25% year-over-year. Faslodex generated $297M in revenue, accounting 0.37% of the company's total revenue, down -11.08% year-over-year. FluMist generated $216M in revenue, accounting 0.27% of the company's total revenue, up 23.43% year-over-year. Imfinzi generated $4.24B in revenue, accounting 5.28% of the company's total revenue, up 52.19% year-over-year. Kanuma generated $171M in revenue, accounting 0.21% of the company's total revenue, up 6.88% year-over-year. Koselugo generated $331M in revenue, accounting 0.41% of the company's total revenue, up 59.13% year-over-year. Lokelma generated $412M in revenue, accounting 0.51% of the company's total revenue, up 42.56% year-over-year. Lynparza generated $2.81B in revenue, accounting 3.50% of the company's total revenue, up 6.56% year-over-year. Nexium generated $945M in revenue, accounting 1.18% of the company's total revenue, down -26.46% year-over-year. Oncology, Others generated $224M in revenue, accounting 0.28% of the company's total revenue, up 409.09% year-over-year. Onglyza generated $227M in revenue, accounting 0.28% of the company's total revenue, down -11.67% year-over-year. Other, Others generated $231M in revenue, accounting 0.29% of the company's total revenue, down -32.06% year-over-year. Rare Disease generated $7.76B in revenue, accounting 9.68% of the company's total revenue, up 10.08% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of AstraZeneca was Total Oncology. This segment made a revenue of $17.14B, representing 21.37% of the company's total revenue.